GENERATION BIO CO.-,0001

Squarepoint Ops LLC purchased a new position in Generation Bio Co. (NASDAQ:GBIO – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 65,628 shares of the company’s stock, valued at approximately $70,000. Squarepoint Ops LLC owned approximately 0.10% of Generation Bio as of its most recent SEC filing. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new stake in shares of Generation Bio in the 4th quarter valued at approximately $25,000. Integrated Wealth Concepts LLC acquired a new position in shares of Generation Bio in the 4th quarter worth approximately $77,000. Millennium Management LLC acquired a new position in shares of Generation Bio in the 4th quarter worth approximately $97,000. Deutsche Bank AG raised its holdings in shares of Generation Bio by 688.7% in the 4th quarter. Deutsche Bank AG now owns 184,173 shares of the company’s stock worth $195,000 after buying an additional 160,822 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Generation Bio by 74.9% in the 4th quarter. JPMorgan Chase & Co. now owns 297,705 shares of the company’s stock worth $316,000 after buying an additional 127,513 shares in the last quarter. Institutional investors own 95.22% of the company’s stock. Analysts Set New Price Targets A number of equities analysts have recently issued reports on GBIO shares. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Generation Bio in a report on Thursday, May 8th. Canaccord Genuity Group reissued a “buy” rating and issued a $9.00 target price on shares of Generation Bio in a report on Monday, March 17th. Finally, Wedbush reissued an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a report on Friday, March 14th. View Our Latest Research Report on Generation Bio Generation Bio Price Performance GBIO stock opened at $0.43 on Wednesday. The business has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.69. Generation Bio Co. has a fifty-two week low of $0.32 and a fifty-two week high of $3.65. The stock has a market capitalization of $28.50 million, a price-to-earnings ratio of -0.19 and a beta of 2.66. Generation Bio (NASDAQ:GBIO – Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $1.70 million. On average, equities analysts expect that Generation Bio Co. will post -1.75 earnings per share for the current fiscal year. About Generation Bio (Free Report) Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.» Mehr auf defenseworld.net

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D.» Mehr auf globenewswire.com

Generation Bio Co. (GBIO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $1.12 per share a year ago.» Mehr auf zacks.com